Lintuzumab (SGN-33)

lintuzumab · Seagen Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Lintuzumab (SGN-33), covering 2015-01-07 to 2015-01-07. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML [Phase 2]